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were calculated for each treatment strategy and severity level. Four types of items 
were surveyed: treatment strategy for VCF (A.hospitalization only, B.hospitalization 
to outpatient, C.outpatient visit only, D.operation, E.follow-up only, F.other), treat-
ment period of each VCF therapy (length of stay and outpatient visit), examination
items (diagnostic imaging, laboratory test) and therapeutic regimens (use of cast or 
hard/soft corset, rehabilitation, nerve block, medication). Severity of VCF was classi-
ﬁ ed into three levels: status1(lumbar back pain;/ADL impairment;-/neurological 
symptoms;-), status2(//), status3(//). RESULTS: The questionnaire was 
addressed to 83 institutions, and responses from 68 (response rate 82%) were received. 
Of these, 65 responses were available for estimation. When considering the propor-
tions of treatment strategies (A to C), the expected medical costs for each status were: 
status1; US$1637, status2; US$4485 and status3; US$7962 (1US$  92JPY). The 
expected medical cost of CMM for a patient with osteoporotic VCF in Japan was 
estimated at US$4,032, and the total annual costs of CMM for VCF on a national 
scale were estimated to be US$1.18 billion. CONCLUSIONS: Japan being an aging 
society, the burden of illness for VCF is a signiﬁ cant issue. Further standardization
and customization of treatment modalities are expected for optimal allocation of 
medical resources.
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AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS
OF RITUXIMAB AND ABATACEPT IN THE TREATMENT OF MODERATE
TO SEVERE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE
RESPONSE TO A TUMOUR NECROSIS FACTOR INHIBITOR IN CANADA
Yunger S, Mistry B
Hoffmann-La Roche, Mississauga, ON, Canada
OBJECTIVES: Rituximab (RTX) and abatacept (ABAT) are novel therapies to treat 
moderate to severe Rheumatoid Arthritis (RA). This analysis was conducted to evalu-
ate the cost-effectiveness of these two therapies in patients with active RA who have
had an inadequate response to anti-tumour necrosis factor (TNF) inhibitor therapies 
from the Ontario Ministry of Health perspective. METHODS: A cost-utility model
was used to evaluate the direct costs and outcomes of a standard Canadian treatment
sequence in the absence and presence of either RTX  methotrexate (MTX) or ABAT
 MTX after failure of one anti-TNF. The model simulated 10,000 RA patients over 
a life time. RTX and ABAT were evaluated against the following standard Canadian
treatment sequence after failure of one anti-TNF (etanercept): adalimumab  MTX, 
inﬂ iximab  MTX, leﬂ unomide, gold, cyclosporine and palliative care. Baseline char-
acteristics from REFLEX (Randomized Evaluation of Long-term Efﬁ cacy of Rituximab 
in RA) clinical trial were: mean age, 52.2 years; mean HAQ score, 1.88. ACR response 
rates from RCTs were placebo-adjusted to minimize bias from cross-trial comparisons. 
All relevant direct costs were included in the model including drug costs, administra-
tion and monitoring, and adverse events. Observational data were used to estimate
long-term HAQ progression and average time on treatment for patients responding
to therapy. Costs and beneﬁ ts were discounted at 5% per annum. RESULTS: The 
introduction of RTX following failure of one biologic resulted in a gain of 0.443 
QALYs at an additional total cost of $3710 resulting in an ICER of $8380/QALY. 
The introduction of ABAT following failure of one biologic resulted in a gain of 0.387
QALYs at an additional total cost of $18,588 resulting in an ICER of $48,000/QALY.
CONCLUSIONS: Rituximab is economically attractive from a Canadian payer per-
spective and is a cost effective treatment option over abatacept when compared in the
studied population.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported
Outcomes Studies
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IMPACT OF A SUPPORT PROGRAM ON THE TREATMENT COMPLIANCE
IN OSTEOPOROSIS PATIENTS
Guzzo MR1, Muranaka AH2
1Produtos Roche Químicos e Farmacêuticos SA, São Paulo, São Paulo, Brazil, 2Universidade
Federal de São Paulo, Sao Paulo, SP, Brazil
OBJECTIVES: To assess the extension in which the participation of a patient in a
support program contributes with increased osteoporosis treatment compliance. Trials 
demonstrated that the compliance rates to oral bisphosphonates therapy present a 
signiﬁ cant drop along the ﬁ rst year of treatment and continue declining year after year.
The objective of a support program is to provide patient’s support providing informa-
tion about the disease, to interchange experiences with other patients, provide high 
calcium content nutrition tips and proper physical activities. METHODS: Quantita-
tive study conducted through personal and individual interviews using a structured
questionnaire. Two hundred and twenty interviews were conducted with female 
patients that concluded the bisphosphonate treatment, divided in two groups: one 
hundred-two registered and one hundred and eighteen non-registered into a support
program. RESULTS: The average treatment period with bisphosphonate between the
patients registered in the program is of 11 months vs. 4 months for non-registered
patients. The main causes of impact on the continuous use of bisphosphonate of the
patients non-registered in a support program include the treatment side effects (28% 
vs. 11%; p  0.002). From the total of patients interrupting the intake of bisphospho-
nate due to side effects the largest number are due to gastric problems. However, the
patients registered in a support program reach the treatment ﬁ nal (34% vs. 15%; 
p  0.01). CONCLUSIONS: The patients registered in a support program present the
tendency to follow the prescription and remain for a longer time period in the therapy. 
It is perceived that when the patients has access to wider information about the disease, 
which is one of the main objectives of a treatment support program, the therapy dis-
continuation rate due to side effects is lower. Because the patients are aware about 
the occurrence of gastric issues, they properly follow the guidelines, avoiding them
and reaching the treatment ﬁ nal.
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QUALITY OF LIFE AND COMPLIANCE IN GIRLS WITH
ADOLESCENT IDIOPATHIC SCOLIOSIS
Rivett L, Rothberg A
University of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa
OBJECTIVES: The Brace Questionnaire (BrQ) is a recently-developed, condition-
speciﬁ c tool used to measure quality of life (QoL) in subjects treated with spinal 
bracing. While corrective bracing for adolescent idiopathic scoliosis (AIS) has more 
favourable outcomes when patients are compliant, one must appreciate that bracing
itself may be a stressful and traumatic experience, and compliance with a bracing
protocol is likely to be dependent upon patients’ physical, emotional and social well-
being. Using the BrQ we sought to explore relationships between QoL and compliance
with treatment. METHODS: The BrQ was administered to 31 AIS patients after 
a minimum of 1 year of wearing a brace for 1 year. Subjects were 13–16 year-old 
girls with signiﬁ cant deformity (Cobb angles 25–40 degrees). Participants were
divided into two groups according to their level of compliance with the bracing 
protocol. BrQ sub- and total scores were compared between the two groups using the 
t-test for comparison of means. RESULTS: Twenty participants were classiﬁ ed as 
compliant and 11 as non-compliant. Mean total BrQ scores (expressed as %) were 
83.7 for the compliant group and 64.4 for the non-compliant group (p  0.001). The 
compliant group scored signiﬁ cantly higher in six of the eight domains that make 
up the BrQ. Compliant patients had greater vitality and self esteem, and functioned
better in those domains covering physical, emotional and social performance. 
CONCLUSIONS: Poor QoL adversely affects compliance in AIS patients requiring
a brace. Non-compliant patients lack vitality and self esteem, and function poorly 
in the physical, emotional and social domains. Quality of life for adolescents with
idiopathic scoliosis may relate more to psychosocial coping mechanisms than to physi-
cal deformity and its consequences. It is important for remedial programmes to con-
sider personal, peer and family issues as part of improving QoL, promoting compliance 
and correcting deformity.
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PATIENTS SUCCESS CRITERIA AND EXPECTATIONS IN FALLS 
REHABILITATION
Romero S
Department of Veterans Affairs, Gainesville, FL, USA
OBJECTIVES: Performance-based instruments commonly used in clinical settings 
often do not capture important aspects of the patient’s health experience. Therefore, 
the primary aim of this study was to use a patient-reported outcomes (PRO) question-
naire to investigate patient’s success criteria and expectations when receiving rehabili-
tation services related to falls. METHODS: A group of patients (N  50, age  55) 
receiving physical therapy services were enrolled. Inclusion criteria consisted of: com-
munity dwellers with a history of falling, ability to walk 20 ft, and Mini-Mental State
Exam score 24. The Patient’s Perspective Outcome Questionnaire (PPOQ) was
administered at the initial physical therapy evaluation. PPOQ assesses current levels,
success criteria and expected levels for a number of health domains including: mobility,
self-care, interactions with people, community/social life, energy/drive, mental func-
tion, emotional distress, sensory function, and pain. A 100-point scale is used to assess
levels of interference across domains (0  not affected and 100  most affected).
RESULTS: Participants reported highest scores in the energy/drive (53), mobility (47),
and pain (44) domains. Interactions with people (21) and community/social life (31) 
received the lowest scores, suggesting that domains with a strong social component
were not as affected as domains with a strong physical component. Participants 
required signiﬁ cant improvement to consider their treatment successful. The mobility 
and energy/drive domains required signiﬁ cantly larger reductions than the community/
social life, and interactions with people domains (P  0.006). Across all domains, 
participant’s expectation was that the treatment would not meet their success criteria,
indicating that residual levels of impairment were expected after treatment. CONCLU-
SIONS: The results of this study point out that a number of health domains are sig-
niﬁ cantly affected in this population. These patients have treatment expectations that
exceed the mobility problems for which they were treated. In exploring meaningful 
change, the patient’s expectations and success criteria must be considered.
PMS39
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WORK PRODUCTIVITY AND ACTIVITY IN RHEUMATOID ARTHRITIS 
PATIENTS WHO USE SUBCUTANEOUS BIOLOGIC THERAPIES
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OBJECTIVES: To assess symptoms, functionality, quality of life (QoL), and work/ 
productivity loss in Rheumatoid Arthritis (RA) patients treated with subcutaneous 
(SC) biologics. METHODS: Patient-reported data from the 2007 Rheumatoid Arthri-
tis Patient Study were analyzed. Symptoms were measured by morning stiffness,
fatigue, and pain scores deﬁ ned on a scale from 0 (no symptom) to 10 (severe
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symptom). The Health Assessment Questionnaire (HAQ) was used to measure func-
tional status (scores 0–3). QoL was measured by the mental (MCS) and physical (PCS) 
component summary scores of the Short Form-8 (SF-8). Work/productivity loss was
measured by the Work Productivity and Activity Impairment (WPAI) instrument. 
Comparisons were made between patients who currently use SC biologics versus those 
who discontinued treatment. RESULTS: Of the 2,200 survey respondents (72%
female; average age  49.6years), 386 (17.5%) used SC biologics. The average dura-
tion of RA was 12.4 years, with 14% reporting severe disease. The patient-reported
mean scores were: morning stiffness 6.6, fatigue 6.8, pain 6.5, HAQ 1.6, MCS 43.9 
and PCS 36.4. Patients reported 61.0% work impairment and 59.2% impairments in 
daily activity. Patients who had discontinued SC biologic therapy (N  124, 32.1%)
reported signiﬁ cantly worse scores in morning stiffness, fatigue, pain, and PCS (all
P  0.05) versus patients currently treated with SC biologics (N  262, 67.9%). 
Patients who discontinued therapy had more work/activity loss; only activity impair-
ment was statistically signiﬁ cant (P  0.05). There was no signiﬁ cant difference in
HAQ scores between groups. CONCLUSIONS: RA patients using current SC biolog-
ics still suffer from serious impairments in symptoms, functional status, QoL, and 
work/productivity. However, patients who discontinued SC biologic therapy have sig-
niﬁ cantly worse symptom scores, physical functioning, and activity impairment com-
pared with those currently being treated. Both ﬁ ndings indicate there is still an unmet
medical need in RA patients.
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UTILITY AND QUALITY OF LIFE OF PATIENTS WITH OSTEOARTHRITIS
TREATED WITH THE CYCLOOXYGENASE INHIBITING NITRIC OXIDE 
DONATOR (CINOD) NAPROXCINOD
Jonsson B1, Pﬁ ster P2, Holmstrom S3, Kobelt G4
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OBJECTIVES: To estimate changes in quality of life (SF36) and utility (SF6) in 
patients treated with naproxcinod, naproxen or placebo for 13 weeks, and to explore
the effect of different disease measures on utility. METHODS: SF36 was available
from 3 international ph 3 clinical trials in 2738 patients with knee or hip osteoarthritis 
comparing 2 doses of naproxcinod (375 and 750 mg bid) to naproxen (500 mg bid) 
and placebo. Efﬁ cacy was based on the pain, function and composite scales of the 
WOMAC™ osteoarthritis index. Co-morbidity measures included hypertension (HT)
which increases with NSAID therapy, body mass index (BMI) and diabetes. Changes
in SF6 and individual SF36 domains were compared between the groups using 
ANOVA and Dunett’s 2-sided test. The effect of the WOMAC™ indices, BP, BMI and 
diabetes on utility scores was explored using multiple regression analysis. RESULTS:
All SF36 subscales except mental health as well as utility changed signiﬁ cantly from 
baseline for all groups, and were correlated with changes in the WOMAC™ indices 
(p  0.001). The change in the active groups was signiﬁ cantly better than placebo for
pain and physical function (0.05), but not signiﬁ cantly different between treatments.
However, absolute changes in utility, pain, physical function and general health were
generally larger for naproxcinod 750 mg than naproxen 500 mg by around 10%.
Utility scores correlated signiﬁ cantly with WOMAC™, and patients with high BMI
and BP or diabetes had lower utility scores and worse WOMAC™ indices. Increase 
in utilities were larger for patients with 750 mg naproxcinod than for the other groups. 
CONCLUSIONS: The slightly larger utility and quality of life changes with naprox-
cinod 750 mg despite a similar effect as naproxen on WOMAC™ may be explained 
by a different side-effect proﬁ le and a neutral blood pressure effect.
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AN ASSESSMENT OF SELF REPORTED OUTCOMES IN A NATIONALLY
REPRESENTATIVE SAMPLE OF ELDERLY PERSON DIAGNOSED WITH
RHEUMATOID ARTHRITIS
Rajpura JR
St. John’s University, Fresh Meadows, NY, USA
OBJECTIVES: To utilize WebTV technology as a tool to measure HRQOL in elderly
persons having Rheumatoid Arthritis (RA) in a nationally representative sample and 
to describe their socio-demographic characteristics, medication use and other treat-
ment choices. METHODS: A cross- sectional online survey research design. Random
digit dialing (RDD) survey procedures were used to draw a sample of 550 elderly 
arthritic individuals from US households across 44 states. A subsample of 79 individu-
als previously diagnosed with RA completed SF-36v2 survey, as part of a larger study.
Eight SF-36 domain scores and Physical and Mental Component Summary (PCS and
MCS) scores were computed and compared with cross-sectional norms for general US
population. RESULTS: Compared to the general population, our study sample per-
formed poorly with respect to all the SF-36 domains except mental health (MH) and 
social functioning (SF) domains. RA is more prevalent in whites (96%) and males 
reported higher scores for all the eight SF-36 domains than females. About 92% of 
the sample reported the use of at least one available OTC arthritic medication; 58% 
of the sample was taking prescription drugs, while about 53% reported having used
natural/herbal remedies for arthritis. A signiﬁ cant difference (p  0.003) was found 
between males and females with respect to only PCS scores. Age was found to correlate 
negatively (p  0.005) with PCS and MCS summary measures, particularly for indi-
viduals 70 years and older. CONCLUSIONS: WebTV is an effective survey administra-
tion tool for measuring HRQOL. As expected, elderly perform poorly on three of the
SF-36 domains (PF, RP, BP) having the most physical factor content. Prescription drug
use is fairly prevalent and use of OTC medications and other forms of treatment is 
popular in the population under study.
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THE EFFECT OF LIFESTYLE CHOICES ON THE RISK OF IMPAIRMENT
IN RHEUMATOID ARTHRITIS PATIENTS: AN ANALYSIS OF AEROBIC
EXERCISE AND CIGARETTE SMOKING
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OBJECTIVES: Through data analysis we will examine and identify the lifestyle factors 
that impact clinical outcomes of Rheumatoid Arthritis (RA) patients. METHODS:
Patients’ self-reported data was collected from the 2008 RA Patient Survey, an Internet 
survey of RA patients. We studied the effects of aerobic exercise (20 minutes a day 
per month), and cigarette smoking on RA patients. Sign and symptom scores for 
morning stiffness, fatigue, and pain are deﬁ ned from 0 (no symptom) to 10 (severe
symptom) within the survey. The Health Assessment Questionnaire (HAQ) was used
to measure functional status scores (0–3). Quality of life was measured by the mental 
component score (MCS) and physical component score (PCS) of the Short-Form 36
(SF-36). Productivity was measured by the Work Productivity and Activity Impairment 
(WPAI) Scale. There were no non-RA controls included in the study. RESULTS: A
total of 2048 respondents were included in the analysis 1001 patients exercised and
584 patients smoked cigarettes. The average age was 51.9 years and average RA 
duration was 11.9 years. Patients’ mean MCS and PCS scores in the exercise (40.7, 
36.7) and non-smoking groups (41.2, 34.4) were signiﬁ cantly higher, than in the non-
exercise (40.0, 31.3) and smoking groups (37.4, 32.7). Overall work and productivity
impairment was 41.5% (exercise) versus 45.4% (non-exercise), and 45.5% (smoking)
versus 42.2% (non-smoking). Signs, symptoms, and HAQ scores were signiﬁ cantly 
better in the exercise and non-smoking groups (all P  0.05). CONCLUSIONS: RA
patients who exercise regularly have higher quality of life scores and clinical outcomes. 
Those that smoke cigarettes have lower quality of life scores and higher symptom/
HAQ scores suggesting that this habit may be detrimental to their clinical outcomes.
These results suggest that these lifestyle choices inﬂ uence the overall risk of impairment 
in RA patients.
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IS THE HEALTH UTILITIES INDEX VALID AND RESPONSIVE IN
ASSESSING PATIENTS WITH ANKYLOSING SPONDYLITIS?
Gooch K1, Feeny DH2, Wong R3, Pangan A1, Revicki D4, van der Heijde D5
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OBJECTIVES: QALYs are an important outcome used in cost-effectiveness analysis. 
The Health Utilities Index Mark 3 (HUI-3) is a self-reported measure covering 8 attri-
butes of health status. Our objective was to assess construct validity and responsiveness 
of HUI-3 in ankylosing spondylitis (AS). METHODS: Data were derived from the 
Adalimumab Trial Evaluating Long-Term Efﬁ cacy and Safety in AS (ATLAS). We speci-
ﬁ ed a priori hypotheses regarding the direction and magnitude of associations expected
between overall and single-attribute HUI-3 scores and other health status and quality
of life measures—SF-36, ASQOL, Bath AS Functional Index (BASFI), Bath AS Disease
Activity Index (BASDAI), and Patient’s Global Assessment (PGA). Using baseline data,
we calculated correlation coefﬁ cients and interpreted them via guidelines suggested by 
Guyatt for negligible, weak, moderate, and strong associations. Responsiveness was 
assessed by calculating standardized response means (SRMs) of HUI-3 scores from
baseline to Week 24 for patients meeting the minimum clinically important differences
(MCID) for the ASQOL (1.8). Responsiveness analysis was limited to patients with 
24-week HUI-3 scores. RESULTS: A total of 295 of the 315 patients enrolled in ATLAS 
were included in the analysis. Mean age was 43 years, 76.3% were male, and mean 
duration of AS was 11 years. Correlation coefﬁ cients between HUI-3 scores and other 
instruments conﬁ rmed 62.2% of the a priori hypothesis, with an additional 24.5% 
being under- or over-estimated by only one category. Results of responsiveness analysis 
demonstrated that there were signiﬁ cant differences in overall HUI-3 (SRM 1.13) and
most single-attribute change scores for patients whose changes were greater than the 
ASQOL MCID vs. those whose changes were MCID. CONCLUSIONS: These results 
suggest that HUI-3 constructs are related to similar constructs in other measures, as
expected. This study provides evidence of cross-sectional and longitudinal construct 
validity of the HUI-3 for deriving utility scores for AS patients.
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VALIDATION OF THE MULTI-ATTRIBUTE HEALTH UTILITY (MAHU)
DERIVED FROM A COMPUTER ADAPTIVE INSTRUMENT, CAT-5D-QOL, 
IN OSTEOARTHRITIS
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OBJECTIVES: We aimed to validate the multi-attribute health utility (MAHU) derived 
from the CAT-5D-QOL, a computer-adaptive instrument composed of 5 domains 
(Walking, Handling Objects, Daily Activities, Pain/Discomfort, and Feelings) in people 
with self-reported osteoarthritis (OA), and to compare it with WOMAC_HUI3, the 
utility derived from the standard disease-speciﬁ c measure in OA. METHODS: Data 
were collected from participants (age 50) who completed questionnaires CAT-5D-
QOL in two waves and WOMAC in one wave of a Canada-wide online survey. To 
assess construct validity, we used multivariable regression to examine the associations
